BIO UV Group (ALTUV) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of BIO UV Group stock €1.30, price €0.79, upside +65.0%, quality 41 out of 100. Rating: strongly undervalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range €0.7600 – €5.94 · fair‑value band €0.9700 – €1.62 · the €0.7880 price screens below the €1.30 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow BIO UV in your weekly email
Every Wednesday you see whether BIO UV is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BIO-UV Group S.A. designs, manufactures, and markets water treatment and disinfectant systems using ultraviolet, salt electrolysis, ozone, and advanced oxidation for individuals and professionals in France, rest of Europe, Asia, the Middle East, the Americas, and internationally.
Show moreShow less
It operates through Products, Solutions, and After-Sales divisions. The company offers disinfection equipment and systems under the triogen, AKERON, 1001 Electrodes, and BIOSEA brands; spare parts; and commissioning services.
It also provides maintenance services comprising inspection and diagnosis; cleaning and replacement of parts; calibration and adjustments; updates and upgrades; and training and technical support services.
The company's products are used in residential and commercial pools, aquariums, aquaculture, industrial water, municipal and domestic water, wastewater and reuse, and ballast water applications. It exports its products. BIO-UV Group S.A. was founded in 2000 and is headquartered in Lunel, France.
Stock analysis
BIO UV Group (ALTUV) currently trades at €0.7880, while our model-based Fair Value estimate is €1.30, implying the stock looks roughly 39% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €3.42 per share, and 19 of the 23 models we run sit above the €0.7880 price.
Bear case: the Asset-Based group reads lowest at €0.2300, and 4 of the 23 models stay below the price. Data coverage for this calculation is low.
Scenario range: €0.9700 (bear) to €1.62 (bull), the price of €0.7880 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Industrials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
BIO UV Group reported revenue of €35.9M in FY2025 versus €33.5M in FY2021, a compound +1.8%/yr. Reported net income was €836K in FY2025, compounding +4.9%/yr from FY2021.
Key figures
Market cap €11.2M Micro · P/E ratio 78.8 · P/S ratio 0.33 · EPS (TTM) €0.0100 · Net margin 0.5% · Return on equity 0.5% · Return on assets (EBIT) 3.0% (5-year average) · Operating margin 5.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 52% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at 3% fair-value upside, at 65%, ALTUV screens cheaper than that median.
Fair Value models
Bear€0.9700Fair Value €1.30Bull€1.62
Price €0.7880 · Upside +65.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.0086 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−9.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.2%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.8%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−36.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−36.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−2.1% vs −9.7%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 3%
2025 sits 381% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−13.0%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about −14.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pollution & Treatment Controls · 86 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "BIO UV Group Fair Value". https://www.fairvalue-calculator.com/stock/ALTUV
Frequently asked questions
Is BIO UV Group (ALTUV) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of €1.30 versus a price of €0.7880, about +65% upside (undervalued).
What is the fair value of ALTUV?
Our model-based fair value for BIO UV Group is €1.30 (as of Nov 4, 2026), built from audited fundamentals. The current price: €0.7880.
What is the quality score of ALTUV?
BIO UV Group has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BIO UV Group (ALTUV)?
Our model-based price target is the fair value of €1.30 (as of Nov 4, 2026) from 23 valuation models. Cautious scenario €0.9700, optimistic scenario €1.62. It is a calculation from audited fundamentals, not an analyst target.
What is the BIO UV Group stock forecast for 2026?
Our models put fair value at €1.30, about +65% upside versus a price of €0.7880 (undervalued). Cautious scenario €0.9700, optimistic scenario €1.62. The calculation is refreshed regularly with new filings.
What is the revenue of BIO UV Group (ALTUV)?
BIO UV Group reported trailing-twelve-month revenue of about €37.3M (latest available figure, as of Nov 4, 2026).
What growth is priced into BIO UV Group (ALTUV)?
For today's price to be fair in a discounted-cash-flow model, BIO UV Group would have to grow free cash flow by -13.0 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.2 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of ALTUV use?
Our models discount BIO UV Group at 9.0 %: a base by market capitalisation (nano), damped by beta 0.34, country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BIO UV Group that is -13.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has BIO UV Group (ALTUV) delivered so far?
Over the past 5 years revenue at BIO UV Group grew +2.2 % a year. The price currently implies free-cash-flow growth of -13.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BIO UV Group (ALTUV) growing?
The median revenue growth in the sector is +7.8 % a year. That is the yardstick for the growth priced into BIO UV Group (-13.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BIO UV Group (ALTUV)?
The free-cash-flow yield on the price is 26.87 %: that much free cash flow BIO UV Group produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BIO UV Group (ALTUV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BIO UV Group it is €1.30 per share (as of Nov 4, 2026), against a price of €0.7880. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is BIO UV Group stock overvalued or undervalued in 2026?
As of Nov 4, 2026, ALTUV trades below its calculated fair value: price €0.7880, fair value €1.30, a gap of about +65% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALTUV?
No. The price is what the market pays today (€0.7880); the fair value is what the company's own numbers justify (€1.30). For BIO UV Group the two are €0.5120 per share apart. That gap is exactly why we show both numbers side by side.
How much is BIO UV Group worth?
The market values BIO UV Group at about €11.2M (market capitalisation, as of Nov 4, 2026). Per share that is €0.7880; our models calculate a fair value of €1.30 per share.
What do the bullish and bearish scenarios say about ALTUV?
Our models span a range for BIO UV Group: cautious scenario €0.9700, base €1.30, optimistic €1.62 per share (as of Nov 4, 2026, price €0.7880). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALTUV?
BIO UV Group trades at a price-to-earnings ratio of 78.8 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €1.30 is built from several models across several years. Other multiples: P/B 0.3, P/S 0.3, EV/EBITDA 7.0.
How solid is the balance sheet of BIO UV Group (ALTUV)?
Balance-sheet figures for BIO UV Group (as of Nov 4, 2026): return on equity 0.5%, debt of 0.15 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is ALTUV from its 52-week high?
BIO UV Group trades at €0.7880, about 52% below its 52-week high of €1.64 and 4% above the low of €0.7600 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €1.30 is for.
Which stocks are comparable to BIO UV Group?
From the same area (Industrials) we also value Veralto Corporation, Zurn Elkay Water Solutions Corporation, Fujian Longking Co, Munters Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BIO UV Group stock attractive at the current price?
The data as of Nov 4, 2026: price €0.7880, calculated fair value €1.30 (+65%), Quality Score 41/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALTUV calculated?
We run BIO UV Group through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €1.30 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BIO UV Group currently trades 39% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BIO UV Group (ALTUV)?
The closing price on Nov 6, 2026 was €0.7880. Our model-based fair value is €1.30, about +65% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BIO UV Group right now?
The large discount to fair value meets weak quality (41/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (€0.9700). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of BIO UV Group
How large is the market capitalisation of BIO UV Group (ALTUV)?
The market capitalisation of BIO UV Group is €11.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BIO UV Group (ALTUV)?
The price-to-sales ratio of BIO UV Group is 0.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BIO UV Group (ALTUV)?
Earnings per share at BIO UV Group are €0.0100 (price ÷ EPS = P/E 78.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BIO UV Group (ALTUV)?
The net margin of BIO UV Group is 0.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BIO UV Group (ALTUV)?
The return on equity (ROE) of BIO UV Group is 0.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BIO UV Group (ALTUV)?
On an EBIT basis the return on assets of BIO UV Group is 3.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BIO UV Group (ALTUV)?
The operating margin of BIO UV Group is 5.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BIO UV Group (ALTUV)?
Revenue at BIO UV Group is growing +2.1% versus a year earlier (3y avg −11.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BIO UV Group (ALTUV)?
Earnings per share at BIO UV Group are growing −50.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does BIO UV Group (ALTUV) carry?
The net debt of BIO UV Group is €11.6M (fiscal year 2025, ≈ 3.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BIO UV Group in the live analysis
One click puts BIO UV Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026